Turning immunity on and off
to
Jeffrey A. Hubbell, Ph.D.
Eugene Bell Professor in Tissue Engineering
Deputy Director for Development
University of Chicago Institute for Molecular Engineering
Summary
Dr. Hubbell uses biomaterials and protein engineering approaches to investigate topics in regenerative medicine and immunotherapeutics. In regenerative medicine, he focuses on biomaterial matrices that mimic the extracellular matrix and on growth factor – extracellular matrix interactions, working in a variety of animal models of regenerative medicine. In immunotherapeutics, he focuses on nanomaterials in vaccines that target lymphoid-resident antigen presenting cells and on protein engineering approaches to deliver antigen to the spleen and liver for inverse vaccines to induce tolerance to protein drugs and in autoimmunity. His interests are both basic and translational, having founded or co-founded five biomedical companies based on his technology, namely Focal, in Boston, acquired by Genzyme; Kuros Biosciences, in Zurich, in the domain of regenerative medicine; Anokion and Kanyos Bio, in Boston, both in the domain of immunological tolerance; and Clostra Bio, in Chicago, in the domain of food allergy.
This page was last updated on Wednesday, August 11, 2021